Semiannual Report — FY2026 H1
What Japan Tissue Engineering Co.,Ltd. reported for the period from 2026-04-01 to 2026-09-30.
Filed 2026-11-12View the original on EDINET
How much it says
49Typical
What moved here
9named for the first time
Its own wording
22terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, performance improved, with revenue reaching ¥1,499,024 thousand and operating income turning positive at ¥51 thousand. In preparation for the European expansion of the LabSite series of human cultured tissues for research use, the Company established the overseas subsidiary Japan Tissue Engineering Europe GmbH on 7 October 2026.
Komori's summary of this document, not the document's own words.49Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
45
Typical
52
Typical
75
Very detailed
15
Almost nothing
41
Thin
27
Almost nothing
100
Very detailed
13
Almost nothing
35
Thin
50
Typical
R&D spend3億円Money spent making new things.
Cash left over-3億円Cash from the business, less what went into equipment.
Spent on equipment76百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.